Elite Pharmaceuticals lifts quarterly sales 10% to $40.1m, led by two in-house generics
The OTCQB-listed generics maker says amphetamine and naltrexone products sold under its own name drove growth, with operating income up about 21% and net income well above it.
Elite Pharmaceuticals, a US maker of niche generic drugs, reported sales of $40.1m for the three months to 30 September 2026, the second quarter of its 2027 financial year. That is $3.8m, or 10.4%, more than a year earlier, implying a prior-year figure of roughly $36.3m.
The company credited the increase to amphetamine and naltrexone products that it markets under its own name. It did not provide a product-level split, so the relative contribution of the two drugs is unknown.
Operating income came in at $9.9m, about 21% higher year on year, meaning profit grew faster than sales. Net income attributable to common shareholders was $17.3m, well above operating income. The information available does not explain the difference, and no margin data or financial guidance accompanied the release, which was published on 12 November.
Management has scheduled a conference call for 13 November, where it is expected to discuss the results. Elite's shares trade on the OTCQB under the symbol ELTP.
Why it matters
- Growth at Elite is being driven by products it sells under its own label, which market-access teams tracking generic amphetamine and naltrexone supply may want to note.
- Operating profit rose about twice as fast as revenue, but the reasons, whether mix, pricing or costs, have not been disclosed.
- The gap between $9.9m of operating income and $17.3m of net income is unexplained in the available figures; the 13 November call may clarify it.
- Results appear to rest on a small number of key products, a point for partners and contract manufacturers assessing supply dependence.
Company's press release (SEC filing): Elite Pharmaceuticals Inc /Nv/ ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
